Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03190967 : T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: 99 Years

- Patients must have histologically confirmed HER2-positive breast cancer for which
standard curative measures do not exist or are no longer effective. HER2 testing must
have been performed in a laboratory accredited by the College of American Pathologists
(CAP) or another accrediting entity.

- Patients must have 1-3 brain metastases, each <3cm by contrast MRI, treated within 6
weeks of study entry with SRS and/or resection. A minimum interval of 3 weeks between
completion of brain SRS and/or resection and the start of treatment in this trial will
be observed to allow proper healing. The presence of concomitant extracranial
metastatic disease is allowed for enrollment.

- Corticosteroids will be allowed at enrollment and during the first month of treatment
with T-DM1 after SRS, up to a dose of no more than 10mg of dexamethasone daily or
equivalent. Patients that need to continue corticosteroids after the initial month
will be allowed to continue in the protocol treatment if no further increase in dose
is necessary. Patients that need increase in dose of corticosteroid after initial
month will be taken off protocol treatment.

- Age greater than or equal to18 years. Because breast cancer is not commonly found in
pediatric population and no dosing or adverse event data are currently available on
the use of temozolomide in combination with T-DM1 in patients <18 years of age,
children are excluded from this study, but will be eligible for future pediatric

- ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to

- Patients must have normal organ and marrow function as defined below:

- leukocytes greater than or equal to 3,000/mcL

- absolute neutrophil count greater than or equal to 1,000/mcL

- platelets greater than or equal to 100,000/mcL

- total bilirubin within normal institutional limits

- AST(SGOT)/ALT(SGPT) <3.0 X institutional upper limit of normal

- creatinine up to 1.5 upper institutional limits OR creatinine clearance greater
than or equal to 60 mL/min/1.73 m^2 for patients with creatinine levels above
institutional normal.

- Alkylating agents as well as other therapeutic agents used in this trial are known to
be teratogenic, women of child-bearing potential and men must agree to use adequate
contraception (hormonal or barrier method of birth control; abstinence) prior to study
entry, for the duration of study participation and for 7 months (women) or 4 months
(men) after treatment completion. Should a woman become pregnant or suspect she is
pregnant while she or her partner is participating in this study, she should inform
her treating physician immediately.

- Ability of subject to understand and the willingness to sign a written informed
consent document.


- Patients who are receiving any other investigational agents.

- Patients unable to speak or understand English, since they cannot complete
neurocognitive evaluation.

- Patients with known leptomeningeal metastatic disease.

- Patients previously treated with whole brain radiation therapy (WBRT).

- Patients with major symptoms or impairments related to brain metastases, such as
aphasia or severe confusion, will be excluded per PI discretion when those symptoms
preclude proper neurocognitive evaluation during the study treatment.

- Patients who have received previous treatment with T-DM1 and had systemic progression
of disease while on it, are ineligible. Patients receiving treatment with T-DM1 whose
only site of disease progression was brain are allowed to enroll in this trial.

- Patients who have received chemotherapy in the previous 3 weeks (6 weeks for
nitrosoureas or mitomycin).

- HBV (HBs Ag positive) or HCV (anti-HCV positive) patients are ineligible because of
potential reactivation of hepatitis virus with temozolomide use.

- Grade greater than or equal to 3 peripheral neuropathy according to (NCI CTCAE)
version 4.0.

- Cerebral Vascular Accident (CVA) or Transitory Ischemic Attack (TIA) in the year
before enrollment, or presence of residual symptoms from CVA that happened more than a
year before.

- Pulmonary Embolism (PE) in the 3 months before enrollment. Anticoagulation is
permitted as long as stable dosage for more than 3 months.

- Impaired cardiac function or clinically significant cardiac disease including the

- New York Heart Association grade III or IV congestive heart failure.

- Myocardial infarction within the last 12 months.

- Subjects with impaired LVEF (<50%).

- Patients with inability to complete brain MRI studies with contrast.

- Patients with breast tissue expanders must have those removed before enrollment.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to temozolomide or T-DM1.

- Patients receiving medications that are strong CYP3A4 inhibitors or inducers are
ineligible. In vitro studies indicate that DM1, the cytotoxic component of T-DM1, is
metabolized mainly by CYP3A4 and to a lesser extent by CYP3A5. Concomitant use of
strong CYP3A4 inhibitors with T-DM1 should be avoided due to the potential for an
increase in DM1 exposure and toxicity. Consider an alternate medication with no or
minimal potential to inhibit CYP3A4.

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, that would limit compliance with study requirements.

- Pregnant women are excluded from this study because temozolomide is an alkylating
agent with the potential for teratogenic or abortifacient effects. Because there is an
unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with temozolomide and/or T-DM1, breastfeeding should be
discontinued if the mother is treated with either of those agents. These potential
risks may also apply to other agents used in this study.

- HIV-positive patients are excluded because these patients are at increased risk of
lethal infections when treated with marrow-suppressive therapy.

- Patients with any other concomitant or prior invasive malignancies are ineligible.
However, patients with prior cancer treated with a curative intent with no evidence of
recurrent disease 5 years following diagnosis and judged by the investigator to be at
low risk of recurrence are eligible. Patients with treated limited stage basal cell or
squamous cell carcinoma of the skin or carcinoma in situ of the breast or cervix are
LinksPermanent Link to THIS page:      |      Link to official listing
Bethesda, Maryland
Facility: National Institutes of Health Clinical Center
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office Phone: 888-624-1937
Email not avaialable

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557

Website Design By
World Wide Websites